Old Mission Capital LLC recently announced the acquisition of new stake in Genetic Technologies Limited (NASDAQ:GENE). This fresh investment now brings its stake to 0.22% valued currently at $31154.0. In addition, Millennium Management LLC raised its holdings by 5496.0 to 20621.0 shares.
With over 0.17 million Genetic Technologies Limited (GENE) shares trading Tuesday and a closing price of $0.94 on the day, the dollar volume was approximately $0.16 million. The shares have shown a negative half year performance of -34.89% and its price on 01/24/23 lost nearly -4.66%. Currently, there are 15.39M common shares owned by the public and among those 13.45M shares have been available to trade.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for GENE have a consensus price objective of $25.65. The analysts have set the share’s price value over the next 12 months at a high of $25.65 and a low of $25.65. But an upside of 96.34% will see the stock hit the forecast high price target while median target price for the stock is $25.65.
Fidelity Nasdaq Composite Index F owns 2511.0 shares of the company’s stock, all valued at over $2335.0.
Shares of Genetic Technologies Limited (NASDAQ: GENE) opened at $1.02, up $0.04 from a prior closing price of $0.98. However, the script later moved the day high at 1.0242, down -4.66%. The company’s stock has a 5-day price change of -10.66% and -20.50% over the past three months. GENE shares are trading 0.87% year to date (YTD), with the 12-month market performance down to -52.02% lower. It has a 12-month low price of $0.91 and touched a high of $2.12 over the same period. GENE has an average intraday trading volume of 30.45K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.02%, -11.92%, and -28.42% respectively.
Institutional ownership of Genetic Technologies Limited (NASDAQ: GENE) shares accounts for 1.00% of the company’s 15.39M shares outstanding. Mutual fund holders own 0.02%, while other institutional holders and individual stakeholders account for 1.00% and — respectively.
It has a market capitalization of $18.19M and a beta (3y monthly) value of 1.82. The earnings-per-share (ttm) stands at -$0.32. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.31% over the week and 5.20% over the month.
The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0.
Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
